CA2192103C - Biomatrix for tissue regeneration - Google Patents
Biomatrix for tissue regeneration Download PDFInfo
- Publication number
- CA2192103C CA2192103C CA002192103A CA2192103A CA2192103C CA 2192103 C CA2192103 C CA 2192103C CA 002192103 A CA002192103 A CA 002192103A CA 2192103 A CA2192103 A CA 2192103A CA 2192103 C CA2192103 C CA 2192103C
- Authority
- CA
- Canada
- Prior art keywords
- implant
- gel matrix
- bearing member
- load bearing
- defect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
- A61B17/1146—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis of tendons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06066—Needles, e.g. needle tip configurations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/08—Muscles; Tendons; Ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30988—Other joints not covered by any of the groups A61F2/32 - A61F2/4425
- A61F2/3099—Other joints not covered by any of the groups A61F2/32 - A61F2/4425 for temporo-mandibular [TM, TMJ] joints
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30224—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
Abstract
This invention is an implant (1) for repair of a tissue defect which implant (1) comprises a strand or suture material (2) and a gel matrix (4) containing reparative cells (6) which has been contracted around central portion (8) of suture (2). Suture (2) has free ends (10 and 12) which are used to rejoin the tissue adjacent the defect. Free ends (10 and 12) can be sewn into the body of the tissue thereby holding the ends of the tendon in place and also holding gel matrix (4) in position in the defect.
Description
WO 95133421 ~ ~ y ~ ~ ' r PCT/US95107066 $IObIATRIX FOR TISSUE REGENERATION
In the context of skeletal tissue repair, tissue regeneration therapy is the local application of autologous (host-derived) cells to promote reconstruction of tissue defects caused by trauma, disease or surgical procedures. The objective of the tissue regeneration therapy approach is to deliver high densities of repair-competent cells (or cells that can become competent when influenced by the local environment) to the defect site in a format that optimizes both initial wound mechanics and eventual neotissue production. For soft tissue repair, it is likely that an implant vehicle(s), will be required to 1) transport and constrain the autologous cells in the defect site and 2) provide initial mechanical stability to the surgical site. In an optimal system, it is likely that the vehicle will slowly biodegrade at a rate comparable to the production of neotissue and development of strength in the reparative tissue (1).
The tissue regeneration therapy approach contrasts significantly With more passive approaches to wound repair in which no attempt is made to deliver or to recruit reparative cells to the defect site. For example, in the case of anterior cruciate ligament (ACL) repair with synthetic (presumably ~~inert°) polymer -I-SUBSTITUTE SHEET (RULE 26j R'O 95133421 219 2 ~ p 3 ' , PCTIUS95107066 grafts, the healing process depends entirely on local cellular responses to initiate and control the incorporation of a permane~~,;~iin~7:ant (2) .
Recently, more active devices have been tested using matrix scaffolds designed to deliver and/or to direct cellular processes. These have included, for example, tendon or ACh repair (3-7), meniscus repair (8-II) and articular cartilage repair i12-IS). Alternatively, the use of locally delivered peptide factors, intended to stimulate recruitment of reparative cells and their attachment and/or differentiation, have also been investigated (I6-I9).
In perhaps the best documented tendon repair experiments to date, Silver, Dunn and their colleagues have described extensive investigations of the performance of collagen fiber prostheses for Achilles tendon (3-5) and anterior cruciate ligament (ACL) (6,7) repair in rabbits. They report that at 52 weeks postimplantation in the Achilles tendon defect, the reconstructed tendon (prosthesis + repair tissue) was about 66% as strong as the normal tissue for all implants tested, including an autologous tendon graft and glutaraldehyde-or carbodiimide-crosslinked collagen fiber composites (5). Both the autologous implants and the carbodiimide-crosslinked prostheses were observed to biodegrade rapidly, then regain strength rapidly as new tissue was produced. Glutaraldehyde cross-linked prostheses biodegraded much more slowly in the Achilles tendon model and became surrounded by a thick capsule that eventually stopped the degradation process. While the neotendon developed in these studies Was similar to normal, it was not identical.-For example, the crimp angle of the , neotendon collagen was similar to normal tendon in all implants, but tTie length of the neotendon crimp was less , than about 30% of normal for-the collagen prosthetic devices. In addition, the moduli of the neotendons -2_ SUBSTITUTE SHEET (RULE 26) WO 95133421 ~ 19 210 3 L PCT~59510~066 fornled from the more rapidly degrading implants (autologous tendon and_carbodiimide-crosslinked collagen fibers) were significantly lower than for normal tendon.
Finally, the neotendon observed did not assemble with the fascicle microarchitecture of normal tendon. These researchers conclude that the rate of degradation of the F ~sthesis, and the consequent transfer of load to the ' new tissue ma be as i , y mportant as the initial prosthesis tensile strength in determining the ultimate properties of the repair tissue (5). A similar generation of neoligament was observed in the ACL implants after 20 weeks, although the recovery of strength of the tissue may be somewhat slower in the avascular synovial environment (7).
Based on this evidence, it is clear that at least in the healthy animal, repair-competent cells can be recruited from the tissues surrounding defects in tendons and ligaments, and that these cells will initiate the production of neotissue. It remains unclear from these investigations to what extent the recruited cells represented differentiated phenotypes (e. g., tendon fibroblasts), as opposed to undifferentiated pluripotent stem cells, or whether increased numbers of such cells would enhance the rate of synthesis or the microarchitecture and mechanical properties of the neotissue produced.
Many cell-mediated processes related to the production of skeletal tissue depend on the number of cells involved, both in the rate and magnitude of the effect. For example, in the in vitro production of connective tissue, the rate of collagen gel contraction by fibroblasts embedded in the gel is dependent on the number of cells present in the culture (20). A similar gel-contracting activity has also been correlated witY
cell density-dependent secretion of a contraction-promoting factor by endothelial cells (21). In addition, SUBSTITUTE SHEET (RULE 26) WO 95/33421 219 21 ~, ~ w ,~''~ ~ . PGTIU595/07066 the extent of fibroblast orientation in cultures grown on collagen gels-is directly related to the initial cell density (22). This cell orientation effect has been correlated with the observation of "organizing centers"
in the culture; the number of which has been suggested to , be a direct indicator of morphogenetic capacity at the molecular and cellular levels (23).
r Cell density-dependent differentiation was clearly demonstrated in the culture of chick limb bud cells (24). When cultured at very low density (10' cells/35mm dish), these cells do not exhibit chondrogenic or osteogenic properties. At "intermediate" cell culture densities (2 x 10' cells/35mm dish), the cells exhibit the maximum frequency of osteogenesis, while at still higher density (5 x 10' cells) the maximum frequency of chondrocyte phenotypes is observed.
In each instance cited above, the number of cells initially present strongly influences the nature of cell-mediated processes involved in skeletal tissue formation and the rate at which these developmental and physiological processes occur. Therefore, in the reparative processes of skeletal tissues, Caplan and coworkers have hypothesized that some minimum threshold of cell number may be required at the repair site before formation of "normal" neotissue can occur (25).
Furthermore, in many cases, this minimum threshold may exceed the number of recruitable reparative cells, including less committed cells that can differentiate to repair competent phenotypes; therefore, the extent to which the reparative process can occur may be limited by this single parameter.
Preliminary investigations of the tissue regeneration therapy approach have recently been , conducted in a tendon repair model in the Achilles tendon of the rabbit (25). There were three components to this SUBSTITUTE SHEET (RULE 26) 68975-174 ~ 02192103 2001-04-27 model: the defect, the cells and the vehicle to deliver the cells to the defect site. The delivery vehicle in this model must restrain the cells at the defect site, stabilize the tissue mechanics, then slowly biodegrade as new tissue is produced.
The present invention relates to an implant for repair of a tissue defect, which implant comprises a physiologically compatible load-bearing member having means for securing under tension tissue adjacent to the defect to be repaired, means for supporting a tissue reparative cell mass in the defect and a tissue reparative cell mass supported thereby.
In its simplest form, the invention involves the production of an appropriate polymeric material containing the cells around a fibrous, degradable fixation device which is then employed to secure the cells in the desired anatomic location. This approach is a general surgical method for delivering and securing autologous cells to soft tissue defects, including tendon, ligament, meniscus or muscle, in which the cell delivery device must be fastened at one or both ends to soft tissue interfaces.
In accordance with the invention, there is provided an implant for repair of a tissue defect in a human or non-human animal body, which implant comprises: a physiologically compatible load bearing member; a contracted gel matrix secured to the load bearing member; and mesenchymal stem cells within said contracted gel matrix, said cells having contracted said gel matrix, said matrix being contracted in tension in a given direction.
While one preferred material for the gel matrix employed in the specific example above was composed of purified Type I collagen fibrils, other materials that can likewise be used include, for example, 1) cell-contracted collagen gels 68975-174 cA 02192103 2001-04-27 containing other components of the extracellular matrix, such as proteoglycans or glycosaminoglycans, glycoproteins (fibronectin, laminin, etc.), other collagens (e.g., Types II
or IV), elastin and/or bioactive peptide growth factors or cytokines; 2) other biopolymers such as fibrin; 3) synthetic biodegradable fibers made from such polymers as polylactic or polyglycolic acids, polycaprolactones, or polyamino acids, or their copolymers, which could be cast or wound into or onto the suture; or 4) composite structures such as collagen/polylactic acid structures.
- 5a -W095133421 ' - PCTIUS95107066 In addition to simplesingle-filament sutures, multifilament :devices produced by braiding, weaving or knitting biodegradable fibrous materials including sutures or collagen fibers or-the like can also be used. Cells could in general be attached to such devices by cell- , mediated processes such as contraction of collagen gels, or by non-cell-mediated physical or chemical processes such as r gel-casting gelatin, or a winding of cell-containing fibrous or membranous structures around the device. Such implantation devices could have one or more needles attached at each end of the device to facilitate fixation to soft or hard tissues, and could be of a variety of geometries including planar, cylindrical or tubular construction, depending upon the specific tissue to be repaired, the mode of fixation of the implant and/or the method used to attach the cell-containing biomatrix combination to the implantation device.
The present invention relates to a device and method for implantation of any type of cells that will effect tissue repair.. Although the invention is not limited to any particular cell type, a particularly preferred embodiment includes human mesenchymal stem cells iMSCs), or any of their committed or differentiated progeny.
The cells are preferably obtained from the animal for which the implant is intended, and can preferably be culture expanded prior -to implant. The animal is preferably a human.
In a specific embodiment of this invention, methods have been demonstrated for culturing MSCs or tendon fibroblasts onto double-needle Dexon sutures by causing the cells to contract collagen gels around the central region of the sutures. The autologous cell/collagen gel/suture composite device can be directly implanted between the free ends of full=thickness tendon defects, such as for repair of the human Achilles tendon, ligament such as for repair of the anterior cruciate ligament, or cartilage such as for -s-SUBSTITUTE SHEET (RULE 26) repair of articular cartilage, meniscus, or the disc of the temporomandibular joint.
In the embodiment shown in Figure 1, implant 1 comprises a strand of suture material 2 and a gel matrix 4 containing reparative cells 6 and which has been contracted around central portion 8 of suture 2. Suture 2 has free ends 10 and 12 which are used to rejoin the tissue T
adjacent the defect. As shown free ends 10 and 12 have been sewn into the body of the tissue thereby not only holding the ends of the tendon in place but also holding gel matrix 4 in position in the defect.
Figure 2 shows a mold assembly 15 which can be used to form an implant of the invention. Mold assembly 15 includes mold 16 in which the cell-containing gel matrix is formed around suture 2 which is shown here with needles 3 and 5 at the ends thereof. Tension wire 18 which holds suture 2 under tension in mold I6 and incubation dish 20 in which the matrix preparation is incubated to set the gel.
A specific embodiment of this is described in the example below.
Example 1 A mold assembly was used to prepare an implant for repair of a tissue defect in accordance with the invention.
Small, glass cylinders, 5 mm x 27 mm, which had had their ends fused shut, were cut longitudinally through the center to form glass, canoe-shaped molds. Stiff surgical Wires were bent to form small, bow-shaped tension wires with ends shaped to set just 2 mm deep into the glass molds. The glass mold was placed into a 100 mm culture dish with a suture spanning the tension wire situated in the center of the mold in preparation for the gel suspension to be poured.
_7_ SUBSTITUTE SHEET (RULE 26) WO 95133421 ' PCT/U895/070fifi Autologous mesenchymal stem cells (4 x 10' cells) were suspended in 0.5 ml of 2 X DMEM-LG and mixed thoroughly to create a single-cell suspension. Then 0.5 ml sterilized type I collagen solution (Pancogene S°, Gattefosse SA, Lyon, France; 3 mg/ml; dialyzed into O.OO1M HC1 was added to the cell suspension and pipetted up and down to form a homogenous suspension of cells in the gel. This gel suspension was immediately poured into-the prepared glass mold in the culture dish. The lid was placed over the dish and it was put into the incubator at 37° C for 15-20 minutes to set the gel. After gelation was complete, the dish was flooded with medium without serum until the glass mold was covered and put back into the incubator for 4-6 hours. Contraction of the gel by the cells occurred to the extent that the gel was detached from the walls of the mold and decreased in diameter and length by about 10%. If the cells are cultured in this apparatus for approximately 20 hours, the gel contracts to approximately 60% of its original radial dimension. At the 4 hour time point, the gel was firmly attached to the central suture, such that the suture and tension spring could be lifted out of the medium, the tension spring removed, and the gel implanted in the surgical defect as described.
Tissue repair devices prepared by this procedure were implanted in rabbit Achilles tendon defect model either with or without a Vicryl sheath. Histological observations from these implants at 1, 3 and S weeks indicate that neotendon tissues are formed as early as 1-3 weeks by this procedure. These early neotendon tissues are morphologically similar to tissues produced from tendon cell or MSC implantation in the Vicryl sheath repair model at later timepoints.
_g_ SUBSTITUTE SHEET (RULE 26) 21921'03: i Cited Literature 1. Goodship AE and Cooke P. Bicompatibility of tendon and ligament prostheses. Critical Reviews in Bio n",T,arib117,,~y 1986;2 (4)303-334.
In the context of skeletal tissue repair, tissue regeneration therapy is the local application of autologous (host-derived) cells to promote reconstruction of tissue defects caused by trauma, disease or surgical procedures. The objective of the tissue regeneration therapy approach is to deliver high densities of repair-competent cells (or cells that can become competent when influenced by the local environment) to the defect site in a format that optimizes both initial wound mechanics and eventual neotissue production. For soft tissue repair, it is likely that an implant vehicle(s), will be required to 1) transport and constrain the autologous cells in the defect site and 2) provide initial mechanical stability to the surgical site. In an optimal system, it is likely that the vehicle will slowly biodegrade at a rate comparable to the production of neotissue and development of strength in the reparative tissue (1).
The tissue regeneration therapy approach contrasts significantly With more passive approaches to wound repair in which no attempt is made to deliver or to recruit reparative cells to the defect site. For example, in the case of anterior cruciate ligament (ACL) repair with synthetic (presumably ~~inert°) polymer -I-SUBSTITUTE SHEET (RULE 26j R'O 95133421 219 2 ~ p 3 ' , PCTIUS95107066 grafts, the healing process depends entirely on local cellular responses to initiate and control the incorporation of a permane~~,;~iin~7:ant (2) .
Recently, more active devices have been tested using matrix scaffolds designed to deliver and/or to direct cellular processes. These have included, for example, tendon or ACh repair (3-7), meniscus repair (8-II) and articular cartilage repair i12-IS). Alternatively, the use of locally delivered peptide factors, intended to stimulate recruitment of reparative cells and their attachment and/or differentiation, have also been investigated (I6-I9).
In perhaps the best documented tendon repair experiments to date, Silver, Dunn and their colleagues have described extensive investigations of the performance of collagen fiber prostheses for Achilles tendon (3-5) and anterior cruciate ligament (ACL) (6,7) repair in rabbits. They report that at 52 weeks postimplantation in the Achilles tendon defect, the reconstructed tendon (prosthesis + repair tissue) was about 66% as strong as the normal tissue for all implants tested, including an autologous tendon graft and glutaraldehyde-or carbodiimide-crosslinked collagen fiber composites (5). Both the autologous implants and the carbodiimide-crosslinked prostheses were observed to biodegrade rapidly, then regain strength rapidly as new tissue was produced. Glutaraldehyde cross-linked prostheses biodegraded much more slowly in the Achilles tendon model and became surrounded by a thick capsule that eventually stopped the degradation process. While the neotendon developed in these studies Was similar to normal, it was not identical.-For example, the crimp angle of the , neotendon collagen was similar to normal tendon in all implants, but tTie length of the neotendon crimp was less , than about 30% of normal for-the collagen prosthetic devices. In addition, the moduli of the neotendons -2_ SUBSTITUTE SHEET (RULE 26) WO 95133421 ~ 19 210 3 L PCT~59510~066 fornled from the more rapidly degrading implants (autologous tendon and_carbodiimide-crosslinked collagen fibers) were significantly lower than for normal tendon.
Finally, the neotendon observed did not assemble with the fascicle microarchitecture of normal tendon. These researchers conclude that the rate of degradation of the F ~sthesis, and the consequent transfer of load to the ' new tissue ma be as i , y mportant as the initial prosthesis tensile strength in determining the ultimate properties of the repair tissue (5). A similar generation of neoligament was observed in the ACL implants after 20 weeks, although the recovery of strength of the tissue may be somewhat slower in the avascular synovial environment (7).
Based on this evidence, it is clear that at least in the healthy animal, repair-competent cells can be recruited from the tissues surrounding defects in tendons and ligaments, and that these cells will initiate the production of neotissue. It remains unclear from these investigations to what extent the recruited cells represented differentiated phenotypes (e. g., tendon fibroblasts), as opposed to undifferentiated pluripotent stem cells, or whether increased numbers of such cells would enhance the rate of synthesis or the microarchitecture and mechanical properties of the neotissue produced.
Many cell-mediated processes related to the production of skeletal tissue depend on the number of cells involved, both in the rate and magnitude of the effect. For example, in the in vitro production of connective tissue, the rate of collagen gel contraction by fibroblasts embedded in the gel is dependent on the number of cells present in the culture (20). A similar gel-contracting activity has also been correlated witY
cell density-dependent secretion of a contraction-promoting factor by endothelial cells (21). In addition, SUBSTITUTE SHEET (RULE 26) WO 95/33421 219 21 ~, ~ w ,~''~ ~ . PGTIU595/07066 the extent of fibroblast orientation in cultures grown on collagen gels-is directly related to the initial cell density (22). This cell orientation effect has been correlated with the observation of "organizing centers"
in the culture; the number of which has been suggested to , be a direct indicator of morphogenetic capacity at the molecular and cellular levels (23).
r Cell density-dependent differentiation was clearly demonstrated in the culture of chick limb bud cells (24). When cultured at very low density (10' cells/35mm dish), these cells do not exhibit chondrogenic or osteogenic properties. At "intermediate" cell culture densities (2 x 10' cells/35mm dish), the cells exhibit the maximum frequency of osteogenesis, while at still higher density (5 x 10' cells) the maximum frequency of chondrocyte phenotypes is observed.
In each instance cited above, the number of cells initially present strongly influences the nature of cell-mediated processes involved in skeletal tissue formation and the rate at which these developmental and physiological processes occur. Therefore, in the reparative processes of skeletal tissues, Caplan and coworkers have hypothesized that some minimum threshold of cell number may be required at the repair site before formation of "normal" neotissue can occur (25).
Furthermore, in many cases, this minimum threshold may exceed the number of recruitable reparative cells, including less committed cells that can differentiate to repair competent phenotypes; therefore, the extent to which the reparative process can occur may be limited by this single parameter.
Preliminary investigations of the tissue regeneration therapy approach have recently been , conducted in a tendon repair model in the Achilles tendon of the rabbit (25). There were three components to this SUBSTITUTE SHEET (RULE 26) 68975-174 ~ 02192103 2001-04-27 model: the defect, the cells and the vehicle to deliver the cells to the defect site. The delivery vehicle in this model must restrain the cells at the defect site, stabilize the tissue mechanics, then slowly biodegrade as new tissue is produced.
The present invention relates to an implant for repair of a tissue defect, which implant comprises a physiologically compatible load-bearing member having means for securing under tension tissue adjacent to the defect to be repaired, means for supporting a tissue reparative cell mass in the defect and a tissue reparative cell mass supported thereby.
In its simplest form, the invention involves the production of an appropriate polymeric material containing the cells around a fibrous, degradable fixation device which is then employed to secure the cells in the desired anatomic location. This approach is a general surgical method for delivering and securing autologous cells to soft tissue defects, including tendon, ligament, meniscus or muscle, in which the cell delivery device must be fastened at one or both ends to soft tissue interfaces.
In accordance with the invention, there is provided an implant for repair of a tissue defect in a human or non-human animal body, which implant comprises: a physiologically compatible load bearing member; a contracted gel matrix secured to the load bearing member; and mesenchymal stem cells within said contracted gel matrix, said cells having contracted said gel matrix, said matrix being contracted in tension in a given direction.
While one preferred material for the gel matrix employed in the specific example above was composed of purified Type I collagen fibrils, other materials that can likewise be used include, for example, 1) cell-contracted collagen gels 68975-174 cA 02192103 2001-04-27 containing other components of the extracellular matrix, such as proteoglycans or glycosaminoglycans, glycoproteins (fibronectin, laminin, etc.), other collagens (e.g., Types II
or IV), elastin and/or bioactive peptide growth factors or cytokines; 2) other biopolymers such as fibrin; 3) synthetic biodegradable fibers made from such polymers as polylactic or polyglycolic acids, polycaprolactones, or polyamino acids, or their copolymers, which could be cast or wound into or onto the suture; or 4) composite structures such as collagen/polylactic acid structures.
- 5a -W095133421 ' - PCTIUS95107066 In addition to simplesingle-filament sutures, multifilament :devices produced by braiding, weaving or knitting biodegradable fibrous materials including sutures or collagen fibers or-the like can also be used. Cells could in general be attached to such devices by cell- , mediated processes such as contraction of collagen gels, or by non-cell-mediated physical or chemical processes such as r gel-casting gelatin, or a winding of cell-containing fibrous or membranous structures around the device. Such implantation devices could have one or more needles attached at each end of the device to facilitate fixation to soft or hard tissues, and could be of a variety of geometries including planar, cylindrical or tubular construction, depending upon the specific tissue to be repaired, the mode of fixation of the implant and/or the method used to attach the cell-containing biomatrix combination to the implantation device.
The present invention relates to a device and method for implantation of any type of cells that will effect tissue repair.. Although the invention is not limited to any particular cell type, a particularly preferred embodiment includes human mesenchymal stem cells iMSCs), or any of their committed or differentiated progeny.
The cells are preferably obtained from the animal for which the implant is intended, and can preferably be culture expanded prior -to implant. The animal is preferably a human.
In a specific embodiment of this invention, methods have been demonstrated for culturing MSCs or tendon fibroblasts onto double-needle Dexon sutures by causing the cells to contract collagen gels around the central region of the sutures. The autologous cell/collagen gel/suture composite device can be directly implanted between the free ends of full=thickness tendon defects, such as for repair of the human Achilles tendon, ligament such as for repair of the anterior cruciate ligament, or cartilage such as for -s-SUBSTITUTE SHEET (RULE 26) repair of articular cartilage, meniscus, or the disc of the temporomandibular joint.
In the embodiment shown in Figure 1, implant 1 comprises a strand of suture material 2 and a gel matrix 4 containing reparative cells 6 and which has been contracted around central portion 8 of suture 2. Suture 2 has free ends 10 and 12 which are used to rejoin the tissue T
adjacent the defect. As shown free ends 10 and 12 have been sewn into the body of the tissue thereby not only holding the ends of the tendon in place but also holding gel matrix 4 in position in the defect.
Figure 2 shows a mold assembly 15 which can be used to form an implant of the invention. Mold assembly 15 includes mold 16 in which the cell-containing gel matrix is formed around suture 2 which is shown here with needles 3 and 5 at the ends thereof. Tension wire 18 which holds suture 2 under tension in mold I6 and incubation dish 20 in which the matrix preparation is incubated to set the gel.
A specific embodiment of this is described in the example below.
Example 1 A mold assembly was used to prepare an implant for repair of a tissue defect in accordance with the invention.
Small, glass cylinders, 5 mm x 27 mm, which had had their ends fused shut, were cut longitudinally through the center to form glass, canoe-shaped molds. Stiff surgical Wires were bent to form small, bow-shaped tension wires with ends shaped to set just 2 mm deep into the glass molds. The glass mold was placed into a 100 mm culture dish with a suture spanning the tension wire situated in the center of the mold in preparation for the gel suspension to be poured.
_7_ SUBSTITUTE SHEET (RULE 26) WO 95133421 ' PCT/U895/070fifi Autologous mesenchymal stem cells (4 x 10' cells) were suspended in 0.5 ml of 2 X DMEM-LG and mixed thoroughly to create a single-cell suspension. Then 0.5 ml sterilized type I collagen solution (Pancogene S°, Gattefosse SA, Lyon, France; 3 mg/ml; dialyzed into O.OO1M HC1 was added to the cell suspension and pipetted up and down to form a homogenous suspension of cells in the gel. This gel suspension was immediately poured into-the prepared glass mold in the culture dish. The lid was placed over the dish and it was put into the incubator at 37° C for 15-20 minutes to set the gel. After gelation was complete, the dish was flooded with medium without serum until the glass mold was covered and put back into the incubator for 4-6 hours. Contraction of the gel by the cells occurred to the extent that the gel was detached from the walls of the mold and decreased in diameter and length by about 10%. If the cells are cultured in this apparatus for approximately 20 hours, the gel contracts to approximately 60% of its original radial dimension. At the 4 hour time point, the gel was firmly attached to the central suture, such that the suture and tension spring could be lifted out of the medium, the tension spring removed, and the gel implanted in the surgical defect as described.
Tissue repair devices prepared by this procedure were implanted in rabbit Achilles tendon defect model either with or without a Vicryl sheath. Histological observations from these implants at 1, 3 and S weeks indicate that neotendon tissues are formed as early as 1-3 weeks by this procedure. These early neotendon tissues are morphologically similar to tissues produced from tendon cell or MSC implantation in the Vicryl sheath repair model at later timepoints.
_g_ SUBSTITUTE SHEET (RULE 26) 21921'03: i Cited Literature 1. Goodship AE and Cooke P. Bicompatibility of tendon and ligament prostheses. Critical Reviews in Bio n",T,arib117,,~y 1986;2 (4)303-334.
2. Bonnarens F.O. and Drez, D., Jr. Biomechanica of artificial ligaments and associated problems. In: Jackson DW, Drez Jr. D, Eds. The anterior cruciate de i ,P"t knee-New conceOts in ligament Renaar, St. Louis: C.V. Mosby Co., ' 1987;239-253.
3. Goldstein JD, Tria AJ, Zawadshy JP, Kato YP, Christiansen D, Silver FH. Development of a Reconstituted Collagen Tendon Prosthesis: A preliminary study. J Bone Jt Sux-ia 1989;7IA(8):1183-1191.
4. Hsu SYC, Cheng JCY, Chong YW, Leung PC.
Glutaraldehyde-treated bioprosthetic substitute for rabbit Achilles tendon. Biomaterials 1989;10:258-264.
Glutaraldehyde-treated bioprosthetic substitute for rabbit Achilles tendon. Biomaterials 1989;10:258-264.
5. Kato YP, Dunn MG, Zawadsky JP, Tria AJ, Silver FH.
Regeneration of Achilles tendon with a collagen tendon Prosthesis: Results of a one-year implantation study. 1 Bone Jt Surg I991;73A:561-574.
Regeneration of Achilles tendon with a collagen tendon Prosthesis: Results of a one-year implantation study. 1 Bone Jt Surg I991;73A:561-574.
6. Rato YP, Dunn MG, Tria AJ, Zawadsky JP, Silver FH.
Preliminary assessment of a collagen fiber ACL prosthesis.
Proceedings of the 17th Annual Meeting of the Society for Biomaterials, Abstract 265, Scottsdale Arizona 1991.
Preliminary assessment of a collagen fiber ACL prosthesis.
Proceedings of the 17th Annual Meeting of the Society for Biomaterials, Abstract 265, Scottsdale Arizona 1991.
7. Dunn MG, Tria AJ, Xato YP, Bechler JR, Ochner RS, Zawadsky JP and Silver FFi. Anterior cruciate ligament reconstruction using a composite collagenous prosthesis.
A biomechanical and histologic study in rabbits. Am. T~ __ Sports Med. 1991;20:507-515.
A biomechanical and histologic study in rabbits. Am. T~ __ Sports Med. 1991;20:507-515.
8. Rlompmaker J, Jansen HWB, Veth RPH, de Groot JH, Nijenhuis AJ, Pennings AJ. Porous polymer implant for _g-SUBSTITUTE SHEET (RULE 26) 2192103 ~,~ > t ., .
repair of meniscal lesions: A preliminary study in dogs.
Biomaterials 1991;12:810-8i6.
repair of meniscal lesions: A preliminary study in dogs.
Biomaterials 1991;12:810-8i6.
9. Aenning CE, Lynch MA, Yearout KM, Vequist SW, Stallbaumer RJ, Decker KA. Arthroscopic meniscal repair l using an exogenous fibrin clot. Clin Ortho 1990;252:64-72.
10. Wood DJ, Minns RJ, Strover A. Replacement of the rabbit medial -meniscus with a polyester-carbon fibre bioprosthesis.- Biomaterials 1990; 11: 13-16.
11. Stone RR, Rodkey WG, Webber RJ, McKinney L, Steadman JR. Collagen-based prostheses for meniscal regeneration.
Clin Ortho 1990;252:129-135. ,,
Clin Ortho 1990;252:129-135. ,,
12. Grande DA; Pitman MI, Peterson L, Menche 0, Rlein M.
The repair of--experimentally produced defects in rabbit articular cartilage by autologous chondrocyte transplantation. J Ortho Res 1989;7:208-218.
The repair of--experimentally produced defects in rabbit articular cartilage by autologous chondrocyte transplantation. J Ortho Res 1989;7:208-218.
13. Grande DA. Technique for healing lesions in cartilage. U.S. Patent Number 4,846,835, July 11, 1989.
14. von Schroeder HP, iCwan M, Amiel D, Coutts RD. The use o~ polylactic acid matrix and periosteal grafts for the reconstruction of rabbit knee articular defects. J Biomed Mat Res 1991;25:329-339.
15. Wakitani S, Kimura T, Hirooka A, et al. Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. J Bone Joint Sura 1989;71-B:74-80.
r
r
16. Wang EA, Rosen V, D~Alessandro JS, et al. Recombinant human bone morphogenetic protein induces bone formation.
Biochem 1990;87:220-224. , SUBSTITUTE SHEET (RULE 26) W095133421 ~ ° . ~~ PCT1US95107066
Biochem 1990;87:220-224. , SUBSTITUTE SHEET (RULE 26) W095133421 ~ ° . ~~ PCT1US95107066
17. Syftestad GT, Lucas PA, Ohgushi H, Caplan Al.
Chondrogenesis as an in vitro response to bioactive factors extracted from adult bone and nonskeletal tissues. In:
Thomhill T, SennA, eds. Develor~ment, and diseases of _ cartilage and bone matrix , UCLA Symposium Volume, New York: Alan Liss, Inc., 1987;187-199.
Chondrogenesis as an in vitro response to bioactive factors extracted from adult bone and nonskeletal tissues. In:
Thomhill T, SennA, eds. Develor~ment, and diseases of _ cartilage and bone matrix , UCLA Symposium Volume, New York: Alan Liss, Inc., 1987;187-199.
18. Syftestad GT, Lucas PA, Caplan Al. The in vitro chondrogenic response of limb bud mesenchyme to a water-soluble fraction prepared from demineralized bone matrix.
Differentiation 1985;29:230-237.
Differentiation 1985;29:230-237.
19. Lucas PA, Syftestad GT, Caplan AI. A water-soluble fraction from adult bone stimulates the differentiation of cartilage in explants of embryonic muscle. Differentiation 1988;37:47-52.
20. Bell E, Ivarsson B, Merrill C. Production of a tisaue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro.
Proc Natl Acad Sci USA 1979;76(3):1274-1278.
Proc Natl Acad Sci USA 1979;76(3):1274-1278.
21. Guidry C, Hohn S, Hook M. Endothelial cells secrete a factor that promotes fibroblast contraction of hydrated collagen gels. J Cell Biol 1990;110:519-528.
22. Rlebe RJ, Caldwell H, Milam S. Cells transmit spatial information by orienting collagen fibers. Ma ix 1989;9:451-458.
23. Rlebe RJ, Overfelt TM, Magnuson VL, Steffensen B, Chen D, Zardeneta G. Quantitative assay for morphogenesis indicates the role of extracellular matrix components and G proteins. Proc Natl Acad Sci USA 1991;88:9588-9592.
24. Caplan AI. Effects of the nicotinamide-sensitive teratogen 3-acetylpyridine on chick limb cells in culture.
Exo Cell Res 1970;62:341-355.
SUBSTITUTE SHEET (RULE 26) W0 95133421 PCTlUS95/07066 2192I0~':''w~:. ,
Exo Cell Res 1970;62:341-355.
SUBSTITUTE SHEET (RULE 26) W0 95133421 PCTlUS95/07066 2192I0~':''w~:. ,
25. Caplan AI, Fink DJ, Goto T., Linton AE, Young RG, Wakitani S, Goldberg VM, Haynesworth SE. Mesenchymal Stem Cells and Tissue Repair In: Jackson DW et al., eds. T a Anterior CT~ac~ a a Licrament ~ Current and Future Contents, New York: Raven Presa, Ltd., 1993; 405-417.
s -1a-SUBSTITUTE SHEET (RULE 26)
s -1a-SUBSTITUTE SHEET (RULE 26)
Claims (20)
1. An implant for repair of a tissue defect in a human or non-human animal body, which implant comprises:
a physiologically compatible load bearing member;
a contracted gel matrix secured to the load bearing member; and mesenchymal stem cells within said contracted gel matrix, said cells having contracted said gel matrix, said matrix being contracted in tension in a given direction.
a physiologically compatible load bearing member;
a contracted gel matrix secured to the load bearing member; and mesenchymal stem cells within said contracted gel matrix, said cells having contracted said gel matrix, said matrix being contracted in tension in a given direction.
2. The implant of claim 1 wherein the gel matrix is a collagen gel.
3. The implant of claim 1 or 2 wherein the cells are human mesenchymal stem cells.
4. The implant of any one of claims 1 to 3 wherein the load bearing member is contiguous with and attached to said gel matrix along said given direction between first and second spaced locations for extending across said defect.
5. The implant of claim 4 wherein the load bearing member is elongated in said given direction.
6. The implant of claim 4 or 5 wherein the load bearing member is selected from the group consisting of a single filament, multiple filaments, biodegradable fibrous materials, woven filaments, collagen fibers and at least one flexible, pliable filament.
7. The implant of any one of claims 4 to 6 wherein the load bearing member is preloaded in tension along the given direction during the contracting of said gel matrix.
8. The implant of any one of claims 4 to 7 wherein the load bearing member is at least one filament with respective ends that extend beyond said first and second locations.
9. The implant of any one of claims 4 to 8 wherein the load bearing member exhibits a tensile load while said gel matrix is being contracted, said load being applied to the load bearing member at first and second load bearing member ends with said gel located intermediate said ends.
l0. The implant of claim 4 or 5 wherein the load bearing member is a suture.
11. The implant of claim 4 or 5 wherein the load bearing member is a suture whose ends are for attachment to said tissue with the suture and gel matrix for extending across said defect.
12. An implant for repair of a tissue defect in an animal in need thereof, which implant comprises:
a contracted gel matrix;
a suture embedded contiguous with said gel matrix along an axial direction between first and second spaced locations;
said suture having first and second ends each extending beyond a different location externally said gel matrix; and mesenchymal stem cells within said gel matrix, said matrix being contracted in tension in said axial direction in response to said cells.
a contracted gel matrix;
a suture embedded contiguous with said gel matrix along an axial direction between first and second spaced locations;
said suture having first and second ends each extending beyond a different location externally said gel matrix; and mesenchymal stem cells within said gel matrix, said matrix being contracted in tension in said axial direction in response to said cells.
13. The implant of claim 12 wherein the suture is preloaded with a tensile load during the contracting of said gel matrix.
14. An implant for repair of a tissue defect in an animal in need thereof, which implant comprises:
a cell contracted collagen gel matrix extending in an axial direction;
a load bearing member contiguous with and attached to said gel matrix along said axial direction between first and second spaced locations for extending across said defect; and mesenchymal stem cells within said contracted gel matrix, said matrix being contracted in tension in said axial direction in response to said cells.
a cell contracted collagen gel matrix extending in an axial direction;
a load bearing member contiguous with and attached to said gel matrix along said axial direction between first and second spaced locations for extending across said defect; and mesenchymal stem cells within said contracted gel matrix, said matrix being contracted in tension in said axial direction in response to said cells.
15. Use of an implant according to any one of claims 1 to 14 for the treatment of a soft tissue defect in a human or non-human animal body.
16. The use of claim 15 wherein the soft tissue defect is a tendon effect.
17. The use of claim 15 wherein the soft tissue defect is a cartilage defect.
18. The use of claim 15 wherein the soft tissue defect is an articular cartilage defect.
19. The use of claim 15 wherein the soft tissue defect is a ligament defect.
20. The use of any one of claims 15 to 19 wherein the mesenchymal stem cells are human mesenchymal stem cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25412594A | 1994-06-06 | 1994-06-06 | |
US08/254,125 | 1994-06-06 | ||
PCT/US1995/007066 WO1995033421A1 (en) | 1994-06-06 | 1995-06-05 | Biomatrix for tissue regeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2192103A1 CA2192103A1 (en) | 1995-12-14 |
CA2192103C true CA2192103C (en) | 2002-02-05 |
Family
ID=22963022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002192103A Expired - Lifetime CA2192103C (en) | 1994-06-06 | 1995-06-05 | Biomatrix for tissue regeneration |
Country Status (11)
Country | Link |
---|---|
US (1) | US5855619A (en) |
EP (1) | EP0952792B1 (en) |
JP (1) | JPH10505250A (en) |
AT (1) | ATE247933T1 (en) |
AU (1) | AU686823B2 (en) |
CA (1) | CA2192103C (en) |
DE (1) | DE69531638T2 (en) |
DK (1) | DK0952792T3 (en) |
ES (1) | ES2206509T3 (en) |
PT (1) | PT952792E (en) |
WO (1) | WO1995033421A1 (en) |
Families Citing this family (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863531A (en) * | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
US8795332B2 (en) * | 2002-09-30 | 2014-08-05 | Ethicon, Inc. | Barbed sutures |
US6174333B1 (en) * | 1994-06-06 | 2001-01-16 | Osiris Therapeutics, Inc. | Biomatrix for soft tissue regeneration using mesenchymal stem cells |
US20070231402A1 (en) | 1994-08-02 | 2007-10-04 | Immunopath Profile, Inc. | Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof |
US6974796B1 (en) * | 1999-08-17 | 2005-12-13 | Girsh Leonard S | Therapeutic compositions for treatment of a damaged tissue |
EP0700671B1 (en) * | 1994-09-08 | 2001-08-08 | Stryker Technologies Corporation | Hydrogel intervertebral disc nucleus |
JP4277939B2 (en) * | 1995-01-31 | 2009-06-10 | 有限会社ナイセム | Cell growth factor-producing cell-embedded medical material |
JP2001516261A (en) * | 1997-03-20 | 2001-09-25 | フォーカル・インコーポレーテッド | Biodegradable tissue retractor |
US5931855A (en) | 1997-05-21 | 1999-08-03 | Frank Hoffman | Surgical methods using one-way suture |
JP2002516140A (en) | 1998-05-23 | 2002-06-04 | フォーカル・インコーポレーテッド | How to treat premature rupture of pregnancy (PROM) |
US6458109B1 (en) * | 1998-08-07 | 2002-10-01 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
ES2295021T3 (en) * | 1999-03-25 | 2008-04-16 | Metabolix, Inc. | USE AND MEDICAL APPLICATIONS OF POLYMER POLYMERS (HYDROXIALCANOATS). |
JP4721482B2 (en) * | 1999-05-18 | 2011-07-13 | 株式会社高研 | Nerve reconstruction substrate |
US6710025B1 (en) | 1999-05-26 | 2004-03-23 | The Brigham And Women's Hospital, Inc. | Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin |
CA2374301A1 (en) * | 1999-05-26 | 2000-11-30 | Brigham And Women's Hospital, Inc. | Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin |
EP2348104A1 (en) | 1999-08-05 | 2011-07-27 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US7790678B1 (en) | 1999-08-17 | 2010-09-07 | Immunopath Profile, Inc. | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
US20070037777A1 (en) * | 2005-08-12 | 2007-02-15 | Immunopath Profile, Inc. | Lipid-containing compositions and methods of using them |
US20090274660A1 (en) | 1999-08-17 | 2009-11-05 | Immunopath Profile, Inc. | Pluripotent therapeutic compositions and uses thereof |
MXPA02002268A (en) * | 1999-08-31 | 2003-08-20 | Univ Virginia Commonwealth | Engineered muscle. |
US6737053B1 (en) * | 1999-11-12 | 2004-05-18 | National University Of Singapore | Tissue-engineered ligament |
AU1375301A (en) * | 1999-11-15 | 2001-05-30 | Bio Syntech Canada Inc | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
US6764462B2 (en) | 2000-11-29 | 2004-07-20 | Hill-Rom Services Inc. | Wound treatment apparatus |
US6824533B2 (en) | 2000-11-29 | 2004-11-30 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US20030096411A1 (en) * | 1999-12-07 | 2003-05-22 | George Michalopoulos | Novel long-term three-dimensional tissue culture system |
US6737270B1 (en) | 1999-12-07 | 2004-05-18 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Long-term three dimensional tissue culture system |
DE60004710T2 (en) * | 1999-12-09 | 2004-07-08 | Biosyntech Canada Inc., Laval | MINERAL-POLYMER HYBRID COMPOSITION |
US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
WO2001072241A1 (en) * | 2000-03-24 | 2001-10-04 | Drexel University | Ligament replacement constructs and methods for production and use thereof |
US8114163B2 (en) * | 2000-04-10 | 2012-02-14 | Biomet Manufacturing Corp. | Method and apparatus for adjusting height and angle for a radial head |
US8920509B2 (en) | 2000-04-10 | 2014-12-30 | Biomet Manufacturing, Llc | Modular radial head prosthesis |
US8535382B2 (en) | 2000-04-10 | 2013-09-17 | Biomet Manufacturing, Llc | Modular radial head prostheses |
ATE407647T1 (en) * | 2000-05-22 | 2008-09-15 | Arthur C Coffey | WOUND DRESSING WITH SIS LAYER AND VACUUM CHAMBER |
DE60117984T8 (en) * | 2000-06-29 | 2007-06-14 | Bio Syntech Canada Inc., Laval | COMPOSITION AND METHOD FOR REPAIRING AND REGENERATING CARTIL AND OTHER WOVEN FABRICS |
US6638312B2 (en) | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
US8366787B2 (en) * | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
EP1363685B1 (en) * | 2000-11-24 | 2007-08-08 | Universite Laval | Connective tissue substitutes, method of preparation and uses thereof |
US6855135B2 (en) * | 2000-11-29 | 2005-02-15 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
US6685681B2 (en) * | 2000-11-29 | 2004-02-03 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
AU2020902A (en) * | 2000-12-06 | 2002-06-18 | Robert J Hariri | Method of collecting placental stem cells background of the invention |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
ES2549161T3 (en) * | 2001-02-14 | 2015-10-23 | Anthrogenesis Corporation | Postpartum mammalian placenta, its use and placental stem cells thereof |
IL157350A0 (en) * | 2001-02-14 | 2004-02-19 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
US7011829B2 (en) * | 2001-05-18 | 2006-03-14 | Kanemaru Shin-Ichi | Tissue filler |
US7056331B2 (en) | 2001-06-29 | 2006-06-06 | Quill Medical, Inc. | Suture method |
US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
US8025896B2 (en) * | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
EP1416888A4 (en) | 2001-07-16 | 2007-04-25 | Depuy Products Inc | Meniscus regeneration device and method |
WO2003007786A2 (en) * | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Porous delivery scaffold and method |
WO2003007790A2 (en) * | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
EP1416880B1 (en) * | 2001-07-16 | 2011-03-02 | DePuy Products, Inc. | Cartilage repair apparatus |
US20050027307A1 (en) * | 2001-07-16 | 2005-02-03 | Schwartz Herbert Eugene | Unitary surgical device and method |
WO2003007839A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Devices form naturally occurring biologically derived |
AU2002316696B2 (en) | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Cartilage repair and regeneration scaffold and method |
US9969980B2 (en) * | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
EP1450878A1 (en) * | 2001-10-11 | 2004-09-01 | Hill-Rom Services, Inc. | Waste container for negative pressure therapy |
EP1478313B2 (en) * | 2001-12-26 | 2018-03-07 | KCI Medical Resources | Vented vacuum bandage |
WO2003057307A1 (en) * | 2001-12-26 | 2003-07-17 | Hill-Rom Services, Inc. | Wound vacuum therapy dressing kit |
US7534927B2 (en) * | 2001-12-26 | 2009-05-19 | Hill-Rom Services, Inc. | Vacuum bandage packing |
US8168848B2 (en) | 2002-04-10 | 2012-05-01 | KCI Medical Resources, Inc. | Access openings in vacuum bandage |
US20030212456A1 (en) * | 2002-05-09 | 2003-11-13 | John Lipchitz | Implant for tissue repair |
US7166133B2 (en) | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
US20040166169A1 (en) * | 2002-07-15 | 2004-08-26 | Prasanna Malaviya | Porous extracellular matrix scaffold and method |
AU2003249805A1 (en) * | 2002-07-16 | 2004-02-02 | Bio Syntech Canada Inc. | Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
US6773450B2 (en) * | 2002-08-09 | 2004-08-10 | Quill Medical, Inc. | Suture anchor and method |
US7896856B2 (en) | 2002-08-21 | 2011-03-01 | Robert Petrosenko | Wound packing for preventing wound closure |
US9969977B2 (en) | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
US20040136968A1 (en) * | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
US8100940B2 (en) | 2002-09-30 | 2012-01-24 | Quill Medical, Inc. | Barb configurations for barbed sutures |
US20040088003A1 (en) * | 2002-09-30 | 2004-05-06 | Leung Jeffrey C. | Barbed suture in combination with surgical needle |
US20040151729A1 (en) * | 2002-10-28 | 2004-08-05 | George Michalopoulos | Novel long-term three-dimensional culture system |
US20040101959A1 (en) * | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
KR101042448B1 (en) * | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
CA2506423C (en) * | 2002-12-04 | 2011-04-19 | Cook Incorporated | Method and device for treating aortic dissection |
CA2515594A1 (en) * | 2003-02-13 | 2004-08-26 | Anthrogenesis Corporation | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
EP1608411B1 (en) * | 2003-04-01 | 2010-09-29 | United States Government as represented by the Department of Veteran's Affaires | Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure. |
EP1638615B1 (en) * | 2003-05-08 | 2014-10-29 | Tepha, Inc. | Polyhydroxyalkanoate medical textiles and fibers |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US7413734B2 (en) | 2003-06-27 | 2008-08-19 | Ethicon, Incorporated | Treatment of retinitis pigmentosa with human umbilical cord cells |
US20050025809A1 (en) * | 2003-07-08 | 2005-02-03 | Tepha, Inc. | Poly-4-hydroxybutyrate matrices for sustained drug delivery |
AU2004268560B2 (en) * | 2003-08-22 | 2008-08-21 | Tepha, Inc. | Polyhydroxyalkanoate nerve regeneration devices |
US8257963B2 (en) * | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7927599B2 (en) * | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
GB0322145D0 (en) * | 2003-09-22 | 2003-10-22 | Howmedica Internat S De R L | Apparatus for use in the regeneration of structured human tissue |
EP1677703A4 (en) * | 2003-10-02 | 2009-09-02 | Depuy Spine Inc | Chemical treatment for removing cellular and nuclear material from naturally occurring extracellular matrix-based biomaterials |
JP2007508018A (en) | 2003-10-08 | 2007-04-05 | べト−ステム インコーポレイテッド | Method for preparing and using a novel stem cell composition, and kit containing the composition |
CN101966183A (en) * | 2003-12-02 | 2011-02-09 | 细胞基因公司 | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US7569233B2 (en) * | 2004-05-04 | 2009-08-04 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
US20050249772A1 (en) * | 2004-05-04 | 2005-11-10 | Prasanna Malaviya | Hybrid biologic-synthetic bioabsorbable scaffolds |
US7407511B2 (en) * | 2004-05-13 | 2008-08-05 | Wright Medical Technology Inc | Methods and materials for connective tissue repair |
ES2638301T3 (en) | 2004-05-14 | 2017-10-19 | Ethicon Llc | Suture devices |
EP1778305B1 (en) * | 2004-08-03 | 2010-07-07 | Tepha, Inc. | Non-curling polyhydroxyalkanoate sutures |
US20060045872A1 (en) * | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
ES2264862B8 (en) * | 2004-08-25 | 2017-01-20 | Cellerix, S.L. | BIOMATERIAL FOR SUTURE. |
US8513011B2 (en) * | 2004-08-26 | 2013-08-20 | Biotech Research Ventures Pte Limited | Methods and compositions for culturing cardiomyocyte-like cells |
US7513866B2 (en) * | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
US7354627B2 (en) * | 2004-12-22 | 2008-04-08 | Depuy Products, Inc. | Method for organizing the assembly of collagen fibers and compositions formed therefrom |
CA2589041C (en) | 2004-12-23 | 2019-08-20 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
CA2512667A1 (en) * | 2005-01-07 | 2006-07-07 | Takahiro Ochiya | Human hepatocyte-like cells and uses thereof |
ATE481088T1 (en) * | 2005-01-28 | 2010-10-15 | Tepha Inc | EMBOLIZATION USING POLY-4-HYDROXYBUTYRATE PARTICLES |
US20060222634A1 (en) * | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
WO2006121887A2 (en) * | 2005-05-05 | 2006-11-16 | Cook Biotech Incorporated | Implantable materials and methods for inhibiting tissue adhesion formation |
US20080241112A1 (en) * | 2005-05-10 | 2008-10-02 | Christof Westenfelder | Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media |
US20070042326A1 (en) * | 2005-06-01 | 2007-02-22 | Osseous Technologies Of America | Collagen antral membrane expander |
US7850985B2 (en) * | 2005-07-05 | 2010-12-14 | Cook Biotech Incorporated | Tissue augmentation devices and methods |
US9271817B2 (en) * | 2005-07-05 | 2016-03-01 | Cook Biotech Incorporated | Tissue augmentation devices and methods |
SG10201400793RA (en) | 2005-09-23 | 2014-08-28 | Cellerix Sl | Cell populations having immunoregulatory activity, method for isolation and uses |
CN104138392A (en) | 2005-10-13 | 2014-11-12 | 人类起源公司 | Immunomodulation using placental stem cells |
CA2628244A1 (en) * | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
PL1971681T3 (en) | 2005-12-16 | 2018-01-31 | Depuy Synthes Products Inc | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
EP2471907B1 (en) * | 2005-12-29 | 2018-09-26 | Celularity, Inc. | Placental stem cell populations |
CA2633775A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
US20090306776A1 (en) | 2006-01-25 | 2009-12-10 | Children's Medical Center Corporation | Methods and procedures for ligament repair |
US9339369B2 (en) * | 2006-05-09 | 2016-05-17 | Lifecell Corporation | Reinforced biological tissue |
ITRM20060289A1 (en) * | 2006-05-31 | 2007-12-01 | Ranieri Cancedda | BIO MEMBRANE ENGINEERED OSTEO ANGIOGENICA AND ITS USES FOR THE REGENERATION OF BONE FABRIC |
CA2654716A1 (en) * | 2006-06-09 | 2007-12-21 | Anthrogenesis Corporation | Placental niche and use thereof to culture stem cells |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
CA2664866C (en) * | 2006-09-28 | 2018-08-14 | Children's Medical Center Coporation | Methods and collagen products for tissue repair |
US8562972B2 (en) | 2006-10-23 | 2013-10-22 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
JP2010507462A (en) * | 2006-10-23 | 2010-03-11 | クック・バイオテック・インコーポレーテッド | Processed ECM material with enhanced component profile |
US7943683B2 (en) * | 2006-12-01 | 2011-05-17 | Tepha, Inc. | Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers |
US7871440B2 (en) * | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
US9056151B2 (en) * | 2007-02-12 | 2015-06-16 | Warsaw Orthopedic, Inc. | Methods for collagen processing and products using processed collagen |
EP2915537A3 (en) * | 2007-02-12 | 2015-10-28 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
US20080260794A1 (en) * | 2007-02-12 | 2008-10-23 | Lauritzen Nels J | Collagen products and methods for producing collagen products |
US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
KR101532446B1 (en) | 2007-03-30 | 2015-06-29 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | Method for production of three-dimensional structure of cells |
US20080255612A1 (en) * | 2007-04-13 | 2008-10-16 | Angiotech Pharmaceuticals, Inc. | Self-retaining systems for surgical procedures |
EP2607477B1 (en) | 2007-05-03 | 2020-09-23 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
AT505008B1 (en) | 2007-06-06 | 2008-10-15 | Angewandte Biotechnologie Gmbh | METHOD FOR CULTURING TISSUE CELLS FROM NON-EMBRYOONAL PLURIPOTENTIAL CELLS OF MESENCHYMAL ORIGIN |
JP2010529987A (en) * | 2007-06-15 | 2010-09-02 | ガーネット バイオセラピューティクス インコーポレイテッド | Treatment of diseases and disorders using self-replicating colony-forming cells cultured and grown in vitro |
MX2010003217A (en) * | 2007-09-26 | 2010-07-30 | Celgene Cellular Therapeutics | Angiogenic cells from human placental perfusate. |
ES2488406T3 (en) | 2007-09-27 | 2014-08-27 | Ethicon Llc | Self-retaining sutures that include tissue retention elements with enhanced strength |
US8263065B2 (en) | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
JP2011503064A (en) * | 2007-11-07 | 2011-01-27 | アンスロジェネシス コーポレーション | Treatment of preterm complications |
US8916077B1 (en) | 2007-12-19 | 2014-12-23 | Ethicon, Inc. | Self-retaining sutures with retainers formed from molten material |
CN101902974B (en) * | 2007-12-19 | 2013-10-30 | 伊西康有限责任公司 | Self-retaining sutures with heat-contact mediated retainers |
US8118834B1 (en) | 2007-12-20 | 2012-02-21 | Angiotech Pharmaceuticals, Inc. | Composite self-retaining sutures and method |
US8615856B1 (en) | 2008-01-30 | 2013-12-31 | Ethicon, Inc. | Apparatus and method for forming self-retaining sutures |
WO2009097556A2 (en) * | 2008-01-30 | 2009-08-06 | Angiotech Pharmaceuticals, Inc. | Appartaus and method for forming self-retaining sutures |
BRPI0907787B8 (en) * | 2008-02-21 | 2021-06-22 | Angiotech Pharm Inc | method for forming a self-retaining suture and apparatus for raising the retainers in a suture to a desired angle |
US8641732B1 (en) | 2008-02-26 | 2014-02-04 | Ethicon, Inc. | Self-retaining suture with variable dimension filament and method |
US20090228021A1 (en) * | 2008-03-06 | 2009-09-10 | Leung Jeffrey C | Matrix material |
ES2709687T3 (en) | 2008-04-15 | 2019-04-17 | Ethicon Llc | Self-retaining sutures with bi-directional retainers or unidirectional retainers |
ES2608974T3 (en) * | 2008-08-14 | 2017-04-17 | Mesoblast International Sàrl | Compositions of purified mesenchymal stem cells |
JP5950577B2 (en) * | 2008-08-20 | 2016-07-13 | アンスロジェネシス コーポレーション | Treatment of stroke using isolated placental cells |
WO2010021714A2 (en) * | 2008-08-20 | 2010-02-25 | Anthrogenesis Corporation | Improved cell composition and methods of making the same |
RU2011110736A (en) * | 2008-08-22 | 2012-09-27 | Антродженезис Корпорейшн (Us) | METHODS AND COMPOSITIONS FOR TREATING BONE DEFECTS USING PLACENTAL CELLULAR POPULATIONS |
SG196767A1 (en) | 2008-11-03 | 2014-02-13 | Ethicon Llc | Length of self-retaining suture and method and device for using the same |
MX2011005229A (en) | 2008-11-19 | 2011-06-16 | Anthrogenesis Corp | Amnion derived adherent cells. |
EP2375907B1 (en) * | 2008-11-21 | 2019-02-27 | Celularity, Inc. | Treatment of diseases, disorders or conditions of the lung using placental cells |
WO2010059783A2 (en) | 2008-11-21 | 2010-05-27 | Lifecell Corporation | Reinforced biologic material |
AU2009327382B2 (en) * | 2008-12-19 | 2014-07-17 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
EP2379088B1 (en) * | 2008-12-19 | 2018-02-28 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
AU2009327383B2 (en) * | 2008-12-19 | 2014-08-28 | DePuy Synthes Products, LLC | Regeneration and repair of neural tissue following injury |
US10328103B2 (en) | 2009-01-03 | 2019-06-25 | Ray C. Wasielewski | Medical treatment composition comprising mammalian dental pulp stem cells |
US8470308B2 (en) * | 2009-01-03 | 2013-06-25 | Ray C. Wasielewski | Enhanced medical implant comprising disrupted tooth pulp and tooth particles |
JP5908394B2 (en) | 2009-03-26 | 2016-04-26 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | Human umbilical cord tissue cells as a therapy for Alzheimer's disease |
JP2013506681A (en) | 2009-10-02 | 2013-02-28 | バクスター・インターナショナル・インコーポレイテッド | Hematopoietic stem cells for use in the treatment of kidney injury |
US20110207166A1 (en) * | 2009-11-06 | 2011-08-25 | Sarah Rivkah Vaiselbuh | Human bone marrow microenvironments and uses thereof |
US8690960B2 (en) | 2009-11-24 | 2014-04-08 | Covidien Lp | Reinforced tissue patch |
US9398943B2 (en) * | 2009-11-30 | 2016-07-26 | Covidien Lp | Ventral hernia repair with barbed suture |
WO2011090628A2 (en) | 2009-12-29 | 2011-07-28 | Angiotech Pharmaceuticals, Inc. | Bidirectional self-retaining sutures with laser-marked and/or non-laser marked indicia and methods |
US9121007B2 (en) * | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
CN102933703A (en) | 2010-04-07 | 2013-02-13 | 人类起源公司 | Angiogenesis using placental stem cells |
KR20130092394A (en) | 2010-04-08 | 2013-08-20 | 안트로제네시스 코포레이션 | Treatment of sarcoidosis using placental stem cells |
US8460691B2 (en) | 2010-04-23 | 2013-06-11 | Warsaw Orthopedic, Inc. | Fenestrated wound repair scaffold |
US8790699B2 (en) | 2010-04-23 | 2014-07-29 | Warsaw Orthpedic, Inc. | Foam-formed collagen strand |
CN104706390B (en) | 2010-05-04 | 2017-05-17 | 伊西康有限责任公司 | Laser cutting system and methods for creating self-retaining sutures |
ES2615229T3 (en) | 2010-06-11 | 2017-06-06 | Ethicon, Llc | Suture dispensing tools for endoscopic and robot-assisted surgery and procedures |
CN103097520B (en) | 2010-07-13 | 2017-12-05 | 人类起源公司 | The method for producing NK |
US9677042B2 (en) | 2010-10-08 | 2017-06-13 | Terumo Bct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
JP2014504894A (en) | 2010-11-03 | 2014-02-27 | アンジオテック ファーマシューティカルズ, インコーポレイテッド | Indwelling suture material for eluting drug and method related thereto |
WO2012064902A2 (en) | 2010-11-09 | 2012-05-18 | Angiotech Pharmaceuticals, Inc. | Emergency self-retaining sutures and packaging |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
WO2012129534A2 (en) | 2011-03-23 | 2012-09-27 | Angiotech Pharmaceuticals, Inc. | Self-retaining variable loop sutures |
DE102011018365A1 (en) * | 2011-04-20 | 2012-10-25 | Bernhard Hildebrandt | Implantable biological joint replacement for shoulder and hip for treating osteoarthritis, has movement unit comprising support which determines depth of milling process, or bracket which sets pressure of walker |
PT2714059T (en) | 2011-06-01 | 2019-02-04 | Celularity Inc | Treatment of pain using placental stem cells |
US20130172931A1 (en) | 2011-06-06 | 2013-07-04 | Jeffrey M. Gross | Methods and devices for soft palate tissue elevation procedures |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
CA2855880C (en) * | 2011-11-02 | 2021-01-05 | Mimedx Group, Inc. | Implantable collagen devices and related methods and systems of making same |
EP2782535B1 (en) | 2011-11-24 | 2016-10-19 | Cook Biotech Incorporated | Modifiable medical grafts and related apparatuses |
WO2013126590A2 (en) | 2012-02-21 | 2013-08-29 | Baxter International Inc. | Pharmaceutical composition comprising cd34+ cells |
WO2013158742A2 (en) | 2012-04-18 | 2013-10-24 | Cook Biotech Incorporated | Surgical grafts, and implements for delivering same |
EP2951193A4 (en) | 2013-02-01 | 2017-03-01 | Children's Medical Center Corporation | Collagen scaffolds |
CN115137753A (en) | 2013-02-05 | 2022-10-04 | 细胞结构公司 | Natural killer cells from placenta |
CN105636598B (en) * | 2013-09-02 | 2021-07-23 | 玛芬股份有限公司 | Product comprising extracellular matrix tissue material and osteogenic protein |
WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
CN104758089B (en) | 2014-01-08 | 2018-03-30 | 库克医学技术有限责任公司 | For clogging the ECM bands of percutaneous heart valve leakage |
EP3613841B1 (en) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passive replacement of media |
US10500303B2 (en) | 2014-08-15 | 2019-12-10 | Tepha, Inc. | Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof |
JP6830059B2 (en) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | Scheduled cell feeding |
WO2016094669A1 (en) | 2014-12-11 | 2016-06-16 | Tepha, Inc. | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof |
US10626521B2 (en) | 2014-12-11 | 2020-04-21 | Tepha, Inc. | Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
WO2018066921A2 (en) * | 2016-10-06 | 2018-04-12 | 아주대학교 산학협력단 | Device for supporting semilunar cartilage hoop stress |
US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11043823B2 (en) * | 2017-04-06 | 2021-06-22 | Tesla, Inc. | System and method for facilitating conditioning and testing of rechargeable battery cells |
EP3669651B1 (en) * | 2018-12-21 | 2023-07-05 | UPM-Kymmene Corporation | Cell system and method for storing cells |
JP7403734B2 (en) * | 2019-11-12 | 2023-12-25 | 国立大学法人横浜国立大学 | Fiber carrier-cell-containing gel complex, method for producing the same, and kit for producing fiber carrier-cell-containing gel complex |
CN112972775B (en) * | 2021-03-09 | 2022-04-26 | 四川大学 | Composite hydrogel capable of replacing/repairing temporomandibular joint disc and preparation method and application thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4539716A (en) * | 1981-03-19 | 1985-09-10 | Massachusetts Institute Of Technology | Fabrication of living blood vessels and glandular tissues |
US5567612A (en) * | 1986-11-20 | 1996-10-22 | Massachusetts Institute Of Technology | Genitourinary cell-matrix structure for implantation into a human and a method of making |
US4846835A (en) * | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US5061283A (en) * | 1987-10-30 | 1991-10-29 | Pfizer Hospital Products Group, Inc. | Method for tendon and ligament repair |
US5171273A (en) * | 1989-01-13 | 1992-12-15 | University Of Medicine And Dentistry Of New Jersey | Synthetic collagen orthopaedic structures such as grafts, tendons and other structures |
US5521087A (en) * | 1989-05-10 | 1996-05-28 | Massachusetts Institute Of Technology | Method for producing oriented connective tissue cells in a ligament configuration |
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5266327A (en) * | 1991-02-08 | 1993-11-30 | Agrez Michael V | Enhanced suturing and means therefor |
US5192312A (en) * | 1991-03-05 | 1993-03-09 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5531791A (en) * | 1993-07-23 | 1996-07-02 | Bioscience Consultants | Composition for repair of defects in osseous tissues, method of making, and prosthesis |
US5489304A (en) * | 1994-04-19 | 1996-02-06 | Brigham & Women's Hospital | Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft |
-
1995
- 1995-06-05 DK DK95922199T patent/DK0952792T3/en active
- 1995-06-05 JP JP8501246A patent/JPH10505250A/en not_active Withdrawn
- 1995-06-05 PT PT95922199T patent/PT952792E/en unknown
- 1995-06-05 WO PCT/US1995/007066 patent/WO1995033421A1/en active IP Right Grant
- 1995-06-05 ES ES95922199T patent/ES2206509T3/en not_active Expired - Lifetime
- 1995-06-05 AU AU26968/95A patent/AU686823B2/en not_active Expired
- 1995-06-05 CA CA002192103A patent/CA2192103C/en not_active Expired - Lifetime
- 1995-06-05 DE DE69531638T patent/DE69531638T2/en not_active Expired - Lifetime
- 1995-06-05 EP EP95922199A patent/EP0952792B1/en not_active Expired - Lifetime
- 1995-06-05 AT AT95922199T patent/ATE247933T1/en active
-
1996
- 1996-09-30 US US08/723,360 patent/US5855619A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE247933T1 (en) | 2003-09-15 |
EP0952792B1 (en) | 2003-08-27 |
DE69531638D1 (en) | 2003-10-02 |
EP0952792A1 (en) | 1999-11-03 |
AU2696895A (en) | 1996-01-04 |
DK0952792T3 (en) | 2003-12-08 |
ES2206509T3 (en) | 2004-05-16 |
JPH10505250A (en) | 1998-05-26 |
US5855619A (en) | 1999-01-05 |
WO1995033421A1 (en) | 1995-12-14 |
EP0952792A4 (en) | 1999-11-03 |
AU686823B2 (en) | 1998-02-12 |
PT952792E (en) | 2003-12-31 |
DE69531638T2 (en) | 2004-06-17 |
CA2192103A1 (en) | 1995-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2192103C (en) | Biomatrix for tissue regeneration | |
US6174333B1 (en) | Biomatrix for soft tissue regeneration using mesenchymal stem cells | |
CA2467195C (en) | Matrix for the production of tissue engineered ligaments, tendons and other tissue | |
US6840962B1 (en) | Tissue engineered tendons and ligaments | |
US6348069B1 (en) | Engineering of strong, pliable tissues | |
US4609551A (en) | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites | |
EP3213778B1 (en) | Cells on a support matrix for tissue repair | |
JP4815554B2 (en) | Medical device based on immune neutral silk fiber | |
US9452238B2 (en) | Tissue implant | |
EP0707498B1 (en) | Implantable prosthesis, kit and device for manufacturing the same | |
JP2002506691A (en) | Biopolymer mats used for tissue repair and reconstruction | |
JP2003530912A (en) | Ligament replacement structure and method of manufacture and use thereof | |
US20110190886A1 (en) | Braided tertiary nanofibrous structure for ligament, tendon, and muscle tissue implant | |
Goulet et al. | Tissue-engineered ligament | |
Barnes | Design of an Electrospun Type II Collagen Scaffold for Articular Cartilage Tissue Engineering | |
ZIGANG | Tissue engineering approach to anterior cruciate ligament reconstruction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20150605 |